指南与共识血栓与止血

美国血液学会2023年静脉血栓栓塞症管理指南:易栓症检测

American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing.
指南 / 共识 · Blood Adv · 2023-01-01

美国血液学会(ASH)组织多学科指南专家组,采用GRADE方法制定易栓症检测的循证指南,共形成23条推荐。几乎所有推荐基于极低确定性证据。强烈推荐不对开始使用复方口服避孕药的一般人群进行检测,并对特定临床场景给出条件性推荐。

要点

  • 强烈推荐不对开始使用复方口服避孕药的一般人群进行易栓症检测。
  • 对非手术重大暂时性或激素相关危险因素相关静脉血栓栓塞症患者,条件性推荐进行易栓症检测。
  • 对脑静脉或内脏静脉血栓形成且否则将停用抗凝者,条件性推荐进行易栓症检测。

核心结论

  • 指南针对易栓症检测及相应管理达成23条推荐,几乎所有推荐基于极低确定性证据。
  • 强烈推荐不对开始使用复方口服避孕药的一般人群进行检测。
  • 对特定场景条件性推荐检测,对其他问题条件性推荐不检测。

研究设计与样本

  • 美国血液学会(ASH)组建多学科指南专家组,涵盖临床与方法学专长并尽量减少利益冲突偏倚。
  • 麦克马斯特大学GRADE中心提供后勤支持、进行系统评价并制作证据概要和证据到决策表。
  • 采用推荐分级的评估、制定与评价(GRADE)方法,推荐草案接受公众评论。

主要发现

  • 专家组就易栓症检测及相关管理达成23条推荐。
  • 几乎所有推荐因模型假设而基于极低确定性证据。
  • 对开始使用复方口服避孕药的一般人群,强烈推荐不进行检测。

关键数值与推荐

  • 条件性推荐检测场景包括:与非手术重大暂时性或激素相关危险因素相关的静脉血栓栓塞症患者。
  • 条件性推荐检测场景包括:脑静脉或内脏静脉血栓形成患者,在否则将停用抗凝的情况下。
  • 条件性推荐检测场景包括:有抗凝血酶、蛋白C或蛋白S缺乏家族史者,在考虑对轻微诱发危险因素进行血栓预防及指导避免复方口服避孕药/激素替代治疗时。
  • 条件性推荐检测场景包括:有高风险类型易栓症家族史的孕妇。
  • 条件性推荐检测场景包括:血栓风险低或中等且伴有静脉血栓栓塞症家族史的癌症患者。

临床怎么用

  • 对开始使用复方口服避孕药的一般人群,强烈推荐不进行易栓症检测。
  • 对上述五类特定场景,条件性推荐进行易栓症检测。
  • 对其他所有问题,条件性推荐不进行易栓症检测。

局限性

  • 几乎所有推荐因模型假设而基于极低确定性证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hereditary and acquired thrombophilia are risk factors for venous thromboembolism (VTE). Whether testing helps guide management decisions is controversial. These evidence-based guidelines from the American Society of Hematology (ASH) intend to support decision making about thrombophilia testing. ASH formed a multidisciplinary guideline panel covering clinical and methodological expertise and minimizing bias from conflicts of interest. The McMaster University GRADE Centre provided logistical support, performed systematic reviews, and created evidence profiles and evidence-to-decision tables. The Grading of Recommendations Assessment, Development, and Evaluation approach (GRADE) was used. Recommendations were subject to public comment. The panel agreed on 23 recommendations regarding thrombophilia testing and associated management. Nearly all recommendations are based on very low certainty in the evidence due to modeling assumptions. The panel issued a strong recommendation against testing the general population before starting combined oral contraceptives (COCs) and conditional recommendations for thrombophilia testing in the following scenarios: (a) patients with VTE associated with nonsurgical major transient or hormonal risk factors; (b) patients with cerebral or splanchnic venous thrombosis, in settings where anticoagulation would otherwise be discontinued; (c) individuals with a family history of antithrombin, protein C, or protein S deficiency when considering thromboprophylaxis for minor provoking risk factors and for guidance to avoid COCs/hormone replacement therapy; (d) pregnant women with a family history of high-risk thrombophilia types; and (e) patients with cancer at low or intermediate risk of thrombosis and with a family history of VTE. For all other questions, the panel provided conditional recommendations against testing for thrombophilia.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing. Blood Adv. 2023. PMID: 37195076. doi:10.1182/bloodadvances.2023010177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。